Doctor

Email: [email protected]

1987 B.A., University of Barcelona, Biology

Publications (Selected)

1. Contreras, L., Ricciardi, S., Biffo, S., Muntané, J., & de la Cruz, J. (2025). The many ways to inhibit translation by Sorafenib in liver cancer cells. Molecular and Cellular Biochemistry, 1-18.
2. Contreras, L., Rodríguez-Gil, A., Muntané, J., & de la Cruz, J. (2025). Sorafenib-associated translation reprogramming in hepatocellular carcinoma cells. RNA biology, 22(1), 1-11.
3. de la Cruz-Ojeda, P., Parras-Martínez, E., Rey-Pérez, R., & Muntané, J. (2025). In silico analysis of lncRNA-miRNA-mRNA signatures related to Sorafenib effectiveness in liver cancer cells. World Journal of Gastroenterology, 31(3), 95207.
4. Cruz-Ojeda, P. D. L., Navarro-Villarán, E., Fuertes-Agudo, M., Mata, A., López-Lluch, G., Navas, P., ... & Muntané, J. (2024). Peroxynitrite is involved in the mitochondrial dysfunction induced by Sorafenib in liver cancer cells. Free Radical Biology & Medicine, 229, 251-263.
5. Pieretti, J. C., Horne, T. L., García-Villasante, N., Seabra, A. B., & Muntané, J. (2024). Zinc-based nanoparticles, but not silicon-based nanoparticles, accumulate in mitochondria and promote cell death in liver cancer cells. International Journal of Nanomedicine, 12409-12420.
6. Rodríguez‐Hernández, M. A., González, R., de la Rosa, Á. J., Gallego, P., Ordóñez, R., Navarro‐Villarán, E., ... & Muntané, J. (2019). Molecular characterization of autophagic and apoptotic signaling induced by sorafenib in liver cancer cells. Journal of cellular physiology, 234(1), 692-708.
7. Martín-Bocanegra, I., Horne, T., Maqueda-Hernández, B., Navarro-Villarán, E., & Muntané, J. (2024). Involvement of mTOR signaling in physiopathology and its potential therapeutic interventions. Redox Experimental Medicine, 2024(1).
8. Apostolova, N., Vezza, T., Muntane, J., Rocha, M., & Victor, V. M. (2023). Mitochondrial dysfunction and mitophagy in type 2 diabetes: pathophysiology and therapeutic targets. Antioxidants & Redox Signaling, 39(4-6), 278-320.
9. Roa-Colomo, A., López Garrido, M. Á., Molina-Vallejo, P., Rojas, A., Sanchez, M. G., Aranda-García, V., ... & Garrido-Navas, M. C. (2022). Hepatocellular carcinoma risk-stratification based on ASGR1 in circulating epithelial cells for cancer interception. Frontiers in Molecular Biosciences, 9, 1074277.
10. Dios-Barbeito, S., González, R., Cadenas, M., García, L. F., Victor, V. M., Padillo, F. J., & Muntané, J. (2022). Impact of nitric oxide in liver cancer microenvironment. Nitric Oxide, 128, 1-11.
11. de la Cruz-Ojeda, P., Flores-Campos, R., Navarro-Villarán, E., & Muntané, J. (2022). The role of non-coding RNAs in autophagy during carcinogenesis. Frontiers in cell and developmental biology, 10, 799392.
12. Navarro-Villarán, E., Cruz, P. D. L., Contreras, L., González, R., Negrete, M., Rodríguez-Hernández, M. A., ... & Muntané, J. (2020). Molecular pathways leading to induction of cell death and anti-proliferative properties by tacrolimus and mTOR inhibitors in liver cancer cells.
13. Rodríguez-Hernández, M. A., Chapresto-Garzón, R., Cadenas, M., Navarro-Villarán, E., Negrete, M., Gómez-Bravo, M. A., ... & Muntané, J. (2020). Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells. Cell death & disease, 11(5), 339.

Profile Details

https://www.researchgate.net/profile/Jordi-Muntane